Abstract
In this concise review the role of PET/CT and PET/MRI in the study and management of brain tumors, mainly gliomas and brain metastases will be presented. The radiopharmaceuticals used which are markers for glucose metabolism, amino acid transport, proliferation rate, membrane synthesis, hypoxia, angiogenesis as well as others will be described. The contribution of PET in primary brain tumors concerns identification of tumor, grading and prognosis, biopsy guiding, radiation therapy planning, treatment monitoring and theragnostics and in brain metastases differentiation between recurrence and necrosis and response to radiation therapy respectively.
Keywords
- Brain Metastases
- Biological Tumor Volume (BTV)
- Gastrin-releasing Peptide Receptor Expression
- Gross Tumor Volume (GTV)
- Radiation Necrosis
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Afshar-Oromieh A, Giesel FL, Linhart HG et al (2012) Detection of cranial meningiomas: comparison of 68 Ga-DOTATOC PET/CT and contrast enhanced MRI. Eur J Nucl Med Mol Imaging 39:1409–1415
La Fougère C, Suchorska B, Bartenstein P et al (2011) Molecular imaging of gliomas with PET: opportunities and limitations. Neuro-Oncology 13:806–819
Shi X, Yi C, Wang X et al (2015) 13N-ammonia combined with 18F-FDG could discriminate between necrotic high-grade gliomas and brain abscess. Clin Nucl Med 40:195–199
Heiss P, Mayer S, Herz M et al (1999) Investigation of transport mechanism and uptake kinetics of O-(2-[18F]fluoroethyl)-L-tyrosine in vitro and in vivo. J Nucl Med 40:1367–1373
Chen W, Silverman DH, Delaloye S et al (2006) 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med 47:904–911
Kamson DO, Mittal S, Buth A et al (2013) Differentiation of glioblastomas from metastatic brain tumors by tryptophan uptake and kinetic analysis: a PET study with MRI comparison. Mol Imaging 12:327–337
Kondo A, Ishii H, Aoki S et al (2016) Phase IIa clinical study of [18F] fluciclovine: efficacy and safety of a new PET tracer for brain tumors. Ann Nucl Med 30:608–618
Chen W, Cloughesy T, Kamdar N et al (2005) Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med 46:945–952
Kwee SA, Ko JP, Jiang CS et al (2007) Solitary brain lesions enhancing at MR imaging: evaluation with fluorine18 fluorocholine PET. Radiology 244:557–565
Toyonaga T, Hirata K, Yamaguchi S et al (2016) (18)F-fluoromisonidazole positron emission tomography can predict pathological necrosis of brain tumors. Eur J Nucl Med Mol Imaging 43:1469–1476
Dealing JLJ, Lewis JS, Mc Carthy DW (1998) Redox-active metal complexes for imaging hypoxic tissues: structure activity relationships in copper (II)bis (thiosemicarbazone) complexes. Chem Commun (Camb) 22:2531–2532
Schnell O, Krebs B, Carlsen J et al (2009) Imaging of integrin αvβ3 expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography. Neuro-Oncology 11:861–870
Li D, Zhao X, Zhang L et al (2014) 68Ga-PRGD2 PET/CT in the evaluation of glioma: a prospective study. Mol Pharm 11:3923–3929
Lendvai G, Estrada S, Bergström M et al (2009) Radiolabelled oligonucleotides for imaging of gene expression with PET. Curr Med Chem 16:4445–4461
Allen AM, Ben-Ami M, Reshef A et al (2012) Assessment of response of brain metastases to radiotherapy by PET imaging of apoptosis with 18F-ML-10. Eur J Nucl Med Mol Imaging 39:1400–1408
Strauss LG, Koczan D, Seiz M et al (2012) Correlation of the Ga-68-bombesin analog Ga-68-BZH3 with receptors expression in gliomas as measured by quantitative dynamic positron emission tomography (dPET) and gene arrays. Mol Imaging Biol 14:376–383
Goldman S, Levivier M, Pirotte B et al (1997) Regional methionine and glucose uptake in high- grade gliomas: a comparative study on PET-guided stereotactic biopsy. J Nucl Med 38:1459–1462
Yamaguchi S, Kobayashi H, Hirata K et al (2011) Detection of histological anaplasia in gliomas with oligodendroglial components using positron emission tomography with (18)F-FDG and (11)C-methionine: report of two cases. J Neuro-Oncol 101:335–341
Choi H, Bang JI, Cheon GJ et al (2015) (18)F-fluorodeoxyglucose and (11)C-methionine positron emission tomography in relation to methylguanine methyltransferase promoter methylation in high grade gliomas. Nucl Med Commun 36:211–218
Niyazi M, Schnell O, Suchorska B et al (2012) FET-PET assessed recurrence pattern after radio-chemotherapy in newly diagnosed patients with glioblastoma is influenced by MGMT methylation status. Radiother Oncol 104:78–82
Herholz K (2017) Brain tumors: an update on clinical PET research in gliomas. Semin Nucl Med 47:5–17
Shi X, Zhang X, Yi C et al (2013) The combination of 13N-ammonia and 18F-FDG in predicting primary central nervous system lymphomas in immunocompetent patients. Clin Nucl Med 38:98–102
Pirotte B, Goldman S, Massager N et al (2004) Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas. J Nucl Med 45:1293–1298
Becherer A, Karanikas G, Szabó M et al (2003) Brain tumour imaging with PET: a comparison between [18F]fluorodopa and [11C]methionine. Eur J Nucl Med Mol Imaging 30:1561–1567
Kunz M, Thon N, Eigenbrod S et al (2011) Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. Neuro-Oncology 13:307–316
Dunet V, Rossier C, Buck A et al (2012) Performance of 18F-fluoro-ethyL-tyrosine (18F-FET) PET for the differential diagnosis of primary brain tumor: a systematic review and metaanalysis. J Nucl Med 53:207–214
Nariai T, Tanaka Y, Wakimoto H et al (2005) Usefulness of L-[methyl-11C] methionine-positron emission tomography as a biological monitoring tool in the treatment of glioma. J Neurosurg 103:498–507
Eo JS, Jeong JM (2016) Angiogenesis imaging using 68Ga-RGD PET/CT:Therapeutic implications. Semin Nucl Med 46:419–427
Kawai N, Lin W, Cao WD et al (2014) Correlation between [18F] fluoromisonidazole PET and expression of HIF-1alpha and VEGF in newly diagnosed and recurrent malignant gliomas. Eur J Nucl Med Mol Imaging 41:1870–1878
Tateishi K, Tateishi U, Sato M et al (2013) Application of [62Cu]-diacetyl-bis(N4-methylthiosemicarbazone) PET imaging to predict highly malignant tumor grades and hypoxia-inducible factor 1a expression in patients with glioma. AJNR Am J Neuroradiol 34:92–99
Barker FG 2nd, Chang SM, Huhn SL et al (1997) Age and the risk of anaplasia in magnetic resonance-nonenhancing supratentorial cerebral tumors. Cancer 80:936–941
Law M, Yang S, Wang H et al (2003) Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 24:1989–1998
Pirotte BJ, Lubansu A, Massager N et al (2007) Results of positron emission tomography guidance and reassessment of the utility of and indications for stereotactic biopsy in children with infiltrative brainstem tumors. J Neurosurg 107:392–399
Ling CC, Humm J, Larson S et al (2000) Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol Biol Phys 47:551–560
Lee IH, Piert M, Gomez-Hassan D et al (2009) Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme. Int J Radiat Oncol Biol Phys 73:479–485
Grosu AL, Weber WA, Franz M et al (2005) Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys 63:511–519
Swanson KR, Chakraborty G, Wang CH et al (2009) Complementary but distinct roles for MRI and 18F-fluoromisonidazole PET in the assessment of human glioblastomas. J Nucl Med 50:36–44
Brandsma D, Stalpers L, Taal W et al (2008) Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 9:453–461
Shah R, Vattoth S, Jacob R et al (2012) Radiation necrosis in the brain: imaging features and differentiation from tumor recurrence. Radiographics 32:1343–1359
Torrens M, Malamitsi J, Karaiskos P et al (2016) Although non diagnostic between necrosis and recurrence, FDG PET/CT assists management of brain tumors after radiosurgery. In Vivo 30:513–520
Rachinger W, Goetz C, Pöpperl G et al (2005) Positron emission tomography with O-(2-[18F]fluoroethyl)-L-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery 57:505–511. (discussion 505–511)
Poulsen SH, Urup T, Grunnet K et al (2017) The prognostic value of FET PET at radiotherapy planning in newly diagnosed glioblastoma. Eur J Nucl Med Mol Imaging 44:373–381
Suchorska B, Jansen NL, Linn J et al (2015) Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM. Neurology 84:710–719
Galldiks N, Rapp M, Stoffels G et al (2013) Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI. Eur J Nucl Med Mol Imaging 40:22–33
Wardak M, Schiepers C, Dahlbom M et al (2011) Discriminant analysis of 18F-fluorothymidine kinetic parameters to predict survival in patients with recurrent high-grade glioma. Clin Cancer Res 17:6553–6562
Chen W, Delaloye S, Silverman DH et al (2007) Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 25:4714–4721
Horky LL, Hsiao EM, Weiss SE et al (2011) Dual phase FDG-PET imaging of brain metastases provides superior assessment of recurrence versus post-treatment necrosis. J Neuro-Oncol 103:137–146
Dittmann H, Dohmen BM, Paulsen F et al (2003) [18F]FLT PET for diagnosis and staging of thoracic tumours. Eur J Nucl Med Mol Imaging 30:1407–1412
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Malamitsi, J.V. (2018). PET/CT: Is There a Role?. In: Gouliamos, A., Andreou, J., Kosmidis, P. (eds) Imaging in Clinical Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-68873-2_21
Download citation
DOI: https://doi.org/10.1007/978-3-319-68873-2_21
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-68872-5
Online ISBN: 978-3-319-68873-2
eBook Packages: MedicineMedicine (R0)